Peptide Therapy in Philadelphia

Medically reviewed by Charlie Seltzer, MD, CSCS · Updated October 2026

The peptides everyone's been talking about are finally available from a real doctor. On October 28, 2026, HHS cleared licensed compounders to prepare six of them for individual patients. For years, people bought peptides like BPC-157 and TB-500 online as "research chemicals," with no doctor, no testing and no way to know what was in the vial. Some of those vials had less peptide in them than a Wawa coffee has coffee. Now you can get them the right way: evaluated and prescribed by a physician, compounded to pharmacy standards, and monitored as you go.

The six peptides

Peptide Studied for How it's taken
BPC-157 Tendon, ligament, joint and gut repair Injection, oral or topical
TB-500 Soft-tissue recovery; pairs with BPC-157 Injection
MOTS-c Insulin sensitivity, fat loss, muscle metabolism Injection
Epitalon Sleep, circadian rhythm, healthy aging Injection, intermittent courses
Semax Focus, memory, stress resilience, migraine Nasal spray
KPV Gut and skin inflammation Oral or topical

Gray market vs. Dr. Seltzer

Online "research" peptides Dr. Seltzer Lifestyle Medicine
Source Often unknown, frequently overseas FDA-registered, CGMP ingredient manufacturer
Testing Rarely verified; vials have tested underdosed or contaminated Identity, purity, potency and contaminant testing
Dosing Forum guesswork Set by a physician for you
Screening None Full medical evaluation first
Monitoring None Physician follow-up throughout
Legal status Sold "not for human use" Prescribed and compounded under federal policy

If your peptide came with a "not for human use" sticker and free shipping from a country you can't find on a map, this table is for you.

The new rules in plain English

It's not FDA approval. Under federal law, these six peptides still don't qualify as standard compounding ingredients. HHS is using "enforcement discretion": it won't take action against compounding that follows its rules. HHS put the six on a separate "503A Interim Access List," and the policy runs for each peptide until FDA issues a final rule on it. HHS calls the policy non-binding and says it can revisit it if a safety or quality problem appears.

Who can provide them. State-licensed 503A compounding pharmacies, federal facilities and licensed physicians, always on a patient-specific prescription. Larger 503B outsourcing facilities are not covered, and telehealth companies must fill through a 503A pharmacy.

What you're guaranteed when you go through us. HHS requires compounders to meet all ten of its "appropriate safeguards." Here's what that means for you as a patient:

  1. The exact peptide, in one exact form. Acetate salt for BPC-157, TB-500, MOTS-c, Epitalon and KPV; free base for Semax.
  2. Approved routes only. Semax is nasal only, KPV is oral or topical only, and Epitalon is given in intermittent courses.
  3. One peptide per product. No premixed stacks. A patient on BPC-157 and TB-500 gets two separate products. They can still hang out. They just have to come in separate cars.
  4. A full certificate of analysis on every lot, from the original FDA-registered, CGMP-compliant manufacturer. It covers identity, purity, potency and contaminants such as endotoxins, leftover manufacturing chemicals and nitrosamines. A middleman can't just pass along someone else's paperwork.
  5. Simple delivery only. Injectables ship with a standard FDA-cleared syringe, never pens or auto-injectors. Just a regular syringe, like it's 1985.
  6. Proof oral forms actually absorb. HHS notes oral peptide absorption is difficult, so oral products need documentation that the formulation works in humans.
  7. Mandatory safety reporting. Every serious side effect goes to FDA's MedWatch and to state authorities, even if no one thinks the peptide caused it. Labels must tell patients how to report problems.

State rules still apply. HHS's policy doesn't bind state pharmacy boards, and some states, such as Ohio, still restrict peptides like BPC-157.

What the research says

Most peptide sellers bury the research or skip it. Dr. Seltzer puts it up front, because the best patients are the informed ones.

Peptide Human data Animal data What we're watching
BPC-157 Small pilot studies Strong Theoretical concern with cancer history
TB-500 None for the fragment Moderate No human safety data
MOTS-c None as a treatment yet Strong No human safety data
Epitalon Limited, mostly Russian Moderate FDA flagged possible cancer risk
Semax Russian clinical use Moderate Possible bleeding risk; stimulant interaction
KPV None Moderate No human data; oral and topical only

FDA's staff wanted to keep all six off the market, citing thin human data and the risk of immune reactions to injected peptides. HHS sided with the independent expert panel and opened access, describing the concerns as gaps in information rather than observed harm. For TB-500, HHS called the risk "inferential rather than observed." For KPV, "an absence of information rather than an observed signal." In exchange, every product now comes with strict testing and side-effect reporting to protect patients.

Who should not take peptides

*Medical Disclaimer: The information provided above is for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Peptide therapy is not appropriate for everyone, and individual risks and benefits may vary. Always consult with your physician or qualified healthcare provider before starting peptide therapy to determine whether it is safe and appropriate for your specific medical history, health conditions, and medications.

A real doctor tells you who shouldn't take something. A website selling vials out of a warehouse doesn't. Peptides aren't right for:

  • Anyone pregnant or breastfeeding, or under 18
  • Anyone with an active cancer or a history of cancer (especially BPC-157, TB-500 and Epitalon)
  • Anyone on blood thinners (Semax)
  • Competitive athletes who are drug-tested: BPC-157 and TB-500 are banned by the World Anti-Doping Agency

Policy updates

  • October 27–28, 2026: HHS posts and announces an interim enforcement discretion policy (Federal Register document 2026-22192), signed by Secretary Robert F. Kennedy Jr., opening compounded access to BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV under ten conditions.
  • July 2026: FDA's Pharmacy Compounding Advisory Committee spends two days reviewing seven peptides and narrowly votes for six. The seventh, emideltide, a sleep and pain peptide, is rejected. FDA's own scientists had recommended against all seven.
  • April 2026: FDA unexpectedly moves the seven peptides off its "Category 2" high-risk list, clearing the way for the review.
  • 2023: FDA places these peptides, along with 13 others, on Category 2, effectively barring pharmacies from compounding them and pushing demand to the gray market.

We update this page as the rules change. Which, given how fast Washington moves, may be a while.

Why Dr. Seltzer

Plenty of Philadelphia doctors are rushing to learn about peptide therapy now that the market is booming. Most of them learned about BPC-157 from a pharma rep last Tuesday. Dr. Seltzer learned about it in a gym, years ago, from guys the size of vending machines, and he has been studying peptides like BPC-157 and TB-500 closely ever since. He’ll tell you plainly which peptides he thinks are overhyped or not worth your money, which ones could actually benefit you, and who should skip them entirely. That’s not a sales pitch. That’s medicine, from a private physician who has your best interests at heart.

Dr. Charlie Seltzer is a physician, a certified strength and conditioning specialist, and a natural bodybuilding champion. The peptide world grew up around him. He knows what athletes and high performers have been using, and he knows the medicine behind it. Peptides fit alongside his weight loss, personal training and sports performance programs.

Frequently asked questions

Are peptides legal now?

Six specific peptides are, when prescribed by a physician and compounded under HHS's October 2026 policy. They are still not FDA-approved.

Is this the same as FDA approval?

No. FDA approval requires large human trials. This policy lets licensed pharmacies compound six peptides under strict quality rules while FDA decides whether to add them permanently to the compounding list.

Can a doctor prescribe BPC-157?

Yes. A licensed physician can prescribe BPC-157 and the other five for individual patients.

Can I get a BPC-157 and TB-500 stack?

Yes, as two separate prescriptions. Premixed blends aren't covered.

Why can't I get a peptide pen?

HHS limits delivery to a standard FDA-cleared syringe. It considers pens and auto-injectors an added risk for these products.

Can BPC-157 be taken by mouth?

Oral BPC-157 is allowed, but HHS requires documentation that the oral formulation actually absorbs in humans. Dr. Seltzer will recommend the right form for your goal.

How long will this policy last?

For each peptide, until FDA finishes rulemaking on it, which could take a year or more. We'll update this page as it changes.

Will peptides make me look like Dr. Seltzer?

They're closing the gap faster than he'd like to admit. You'll still have to pick up a barbell, though.

Do you offer virtual visits?

Yes. Dr. Seltzer sees patients in Center City and virtually.

Where is the office?

1429 Walnut Street, Suite 401, Philadelphia, PA 19102.

Start with a consultation

We tell you exactly what these are and aren't. If a peptide site isn't doing the same, ask yourself why.

Book your evaluation →

Official sources

The peptides on this page are compounded drug products and are not FDA-approved. They are available by prescription under the U.S. Department of Health and Human Services' 2026 enforcement discretion policy for 503A compounding. Individual results vary.